Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06609941

Additive Effects of Alternative Nostril Breathing with Pharmacological Management on Dyspnea and Control Pause in Patients with Bronchial Asthma

Bronchial asthma is a widespread chronic condition charactrized by inflammation and narrowing of airways, leading to repeateted episodes of breathlessness, wheezing and labored breathing.Breathing exercises help to manage hyperventilation often seen in asthmatic patients. To handle respiratory complications asthmatics are advised to practise nasal breathing techniques in conjunction with their prescribed medications.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Bronchial Asthma Asthma Bronchial Diseases Dyspnea Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Pathological Conditions, Signs and Symptoms Respiration Disorders Respiratory Hypersensitivity Respiratory Tract Diseases Signs and Symptoms Signs and Symptoms, Respiratory

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Foundation University College of Physical Therapy

Rawalpindi, Punjab Province, 46000, Pakistan

Location status: Recruiting

Location contact

Zara Khalid, DPT, MS-CPPT,PHD

CONTACT

[email protected]

0333-5415822

About this study

Bronchial asthma is a very common chronic disease marked by inflammation and constriction of airways, resulting in recurrent episodes of breathlessness, wheezing and decrease work of breathing. Breathing exercises help to manage hyperventilation associated with asthma. In order to manage respiratory conditions asthmatic patients are encouraged for nasal breathing techniques along with pharmacological management. Hence the objective of the study is to compare the effects of alternative nostril breathing along with pharmacological management versus pharmacological management alone on dyspnea, control pause, asthma control and peak expiratory flow rate in patients with bronchial asthma.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults: aged (18-45 years)
  • Gender: Both males and females
  • Grade1- Grade 4 on Modified MRC dyspnea scale
  • Asthma severity classes (intermediate, mild persistent and moderate persistent asthma) acc. to NAEPP national asthma education and prevention program guidlin

Exclusion criteria

  • Patients having acute exacerbation of COPD or status asthmaticus
  • Patients diagnosed with acute infections
  • Patients unable to follow command/ instructions
  • Asthma patients with >40 sec control pause duration
  • Patients who fall in red zone of asthma action plan (PEFR < 50%)

Treatment and study plan

Alternative nostril breathing

Other

Patients in this group will receive alternative nostril breathing along with pharmacological management. For alternative nostirl breathing patient will be advised to inhale slowly (4sec) and deeply through left nostril.Then hold breath for 2-3 sec. Release right nostril and use right ring finger to close left nostril. Exhale slowly (6sec) and completely through right nostril. Inhale slowly (4sec) and deeply through right nostril. Then hold breath for 2-3sec. Release left nostril and use right thumb to close right nostril. Exhale slowly (6sec) and completely through left nostril. Repeat the cycle.

Pharmacological therapy

Drug

Participants in this group will only be provided with standard pharmacological management for 4 weeks as prescribed by a pulmonologist. For example:

Salbutamol inhaler (Short acting bronchodilator) Saltra inhaler (Selective long acting β2 adrenoceptor agonist) Tiotropium (Anticholinergic) Combivir (Nucleoside analogue - reverse transcriptase inhibitor) etc.

Week 01 and week 02:

Patients will receive medication prescribed by pulmonologist.

Week 03 and week 04:

Patients will receive medication prescribed by pulmonologist.

Primary outcomes

  1. Dyspnea

    Time frame: 4 weeks

    Evaluation will be done using Dyspnea-12 questionnaire for dyspnea

  2. Control pause

    Time frame: 4 weeks

    Stopwatch will be used to measure control pause.

  3. Asthma control

    Time frame: 4 weeks

    Asthma control test (ACT) will be used to evaluate asthma control and peak flow meter for peak expiratory flow rate.

  4. Peak expiratory flow rate.

    Time frame: 4 Weeks

    Peak flow meter will be used to measure peak expiratory flow rate

Study contacts

Contact information is provided by the study sponsor or research team.

Bazkha Tariq Aslam Khawaja, DPT

CONTACT

[email protected]

0333-1281293

Sponsors and collaborators

Lead sponsor

Foundation University Islamabad

Other

Registry information

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Sep 24, 2024
Registry last updated
Sep 24, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.